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ABSTRACT 
An altered small intestinal permeability has been proposed as an important aetiological 
factor in the pathogenesis of inflammatory bowel disease. The relevant literature was 
reviewed. Intestinal permeability to Polyethylene glycol 400 in patients with Crohn' s 
disease, their relatives and healthy controls was examined and the data compared with 
studies of small bowel permeability to other similar sized probes. A new technique of 
analysis of urinary Polythylene Glycol 400 by High Performance Liquid 
Chromatography was described and compared with a previously established HPLC 
method. No evidence of an altered bowel permeability could be found using 
Polyethylene glycol 400 , but the possibility that this may have been related to probe 
size and characteristics can not be excluded . 
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Permeability as used in this dissertation is defined as the recovery from urine within a 
specified time of an orally ingested dose of a specific oral probe. 
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CHAPTER ONE: LITERATURE REVIEW. 
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INTRODUCTION 
An altered permeability of the small intestine has been invoked in the pathogenesis of 
various disorders. In terms of this hypothesis antigens gain entry through an abnormal 
bowel mucosa! wall. A basic knowledge of the anatomy of the bowel wall and the 
physiology of uptake mechanisms is essential to the understanding of any dissertation 
on permeability, and this will be briefly discussed. 
ANATOMY 
The human small bowel is formed within 2 weeks of fertilisation, and is a derivation of 
both foregut and hindgut (Arey 1974) . It is about 6 meters (20 feet) long, and extends 
anatomically from the duodenum to the terminal ileum. The four coats of its 
cylindrically shaped wall are, from within outwards, mucosa, submucosa, muscularis, 
subserosal and serosal layers . 
Intestinal villi (finger-like projections) cover the convoluted mucosa! folds. These villi 
are more numerous , thicker and taller in the jejunum than either the duodenum or the 
ileum, and the jejunum is thus the site of maximal absorption of all ingested foodstuffs 
(Kalser 1985). The villi in turn are lined by a single layer of columnar cells, the latter 
being best developed in the middle third of the villus. These cells are ultimately shed 
from the tip of the villus . Tightly packed micro-villi , (approximately 3000 per cell), 
comprising the brush border, line the luminal cell surfaces and it is through here that 
nutrient absorption ultimately occurs. Each cell, including its microvilli, is lined in its 
entirety by 2 layers of plasma membranes (Shiner 1985). 
Intercellular spaces separate the cells and are larger in the jejunum (0. 75nm) than in the 
ileum (0.35nm) or colon (0.25nm). Aqueous channels on the lateral wall of the cells, 
connect these spaces with the internal cell area. 
The Intercellular spaces are sealed on the lateral aspects of the cells by close apposition 
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between adjacent plasma membranes. This area of cellular contact is termed the tight 
( occluding) junction (Martinez-Palomo and Erlij , 1975). The total mucosal thickness 
of the jejunum is on average 690 micrometres. 
PHYSIOLOGY AND TRANSPORT MECHANISMS 
The mode of transport of any entity is dependant on several factors including the type, 
concentration and ionicity of the substance being transported, and the region of bowel 
involved. 
Active and passive transport mechanisms are involved in transport across the small 
bowel mucosal wall. In general , passive transport (that not involving cellular energy) 
occurs through the intercellular spaces , and is directly related to the luminal 
concentration of the substance. This form of transport is also dependent on the size of 
the intercellular pores and is thus greatest in the jejunum. Transport can also occur 
directly through the gut mucosal lining cells throughout the gastrointestinal tract. This 
pathway of active transport occurs against an electrochemical gradient, and is most 
efficient at low luminal concentrations. 
In addition to these two pathways, a simultaneous bi-directional movement of water and 
solute occurs between the serosal layer and the bowel lumen. The process, whereby 
solutes diffuse through the pores of intestinal cells in a stream of water, has been 
termed "solvent drag" (Fordtran et al, 1965). There is a progressive fall in the bulk 
movement of water, and thus "solvent drag" , from the upper to the more distal small 
bowel (Fordtran et al, 1965). 
Under normal physiological conditions, the small intestinal mucosa displays a certain 
selectivity in its ability to absorb fluid, electrolytes and larger molecules. The precise 
route by which water soluble molecules , which are not selectively taken up by cell 
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mediated intestinal uptake mechanisms, diffuse across the small intestinal mucosa is not 
known (Fordtran et al, 1965). Non-ionic water soluble particles, greater than 4nm in 
diameter are excluded. Previous studies have shown that non-lipid-soluble molecules 
penetrate cell membranes through water-filled pores (Hober and Hober, 1937; Solomon 
1960). The effective pore radius decreases progressively from the jejunum to the ileum 
and is approximately twice the size in the jejunum compared to that in the ileum 
(Fordtran et al, 1965). The exact site of the porous barrier is not known, but a 
constant distribution of water filled pores, some large and many small, is thought to 
exist (Fordtran et al , 1965). While the distribution of pores is constant, the absolute 
number of pores of all sizes is thought to decrease distally through the intestinal tract 
(Loehry et al , 1970; Presnell et al, 1978) . This porous route is thought to be one 
mechanism of permeation of small sized molecules. 
An association between molecular size and the rate of permeation from the small bowel 
lumen to the plasma (or vice versa), has been found in studies in rabbits using water-
soluble substances with a molecular weight range of 60-80000 (Loehry et al, 1970 and 
1973). The inverse relationship of molecular size to quantity absorbed in the serum, 
(and ultimately excreted in the urine) has also been shown to occur with Polyethylene 
Glycol (Westrom et al, 1984). This relationship , however , is not found in the urine 
after intravenous injection and this confirms the sieving effect (related to molecular 
size) of the gut mucosal wall. 
PERMEABILITY IN THE HEALTHY INTESTINE 
Permeability may be comprehended as the facility of a membrane to allow unmediated 
movements of a solute across it (Cooper 1986). It is a function of the bowel luminal 
surface area, the concentration gradient across the gut and the permeability 
characteristics of the gut wall (Weaver et al , 1987). 
The neonatal bowel wall is especially permeable to macromolecules during the 24 hour 
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period after the first ingestion of colostrum. This process, which occurs in man and 
certain other mammalian species, is important for the acquisition of passive immunity 
from colostrum (Kraehenbuhl and Campiche, 1969). With maturation, a process of 
"closure" occurs, whereby larger sized molecules (mw > 1100 daltons) are no longer 
absorbed into the circulation (Westrom et al, 1984a and 1984b)(Westrom et al, 1989). 
Factors underlying this closure are still obscure, but could relate to the development of 
a differentiated columnar epithelium (Colony and Neutra, 1985), dietary factors 
(Loehry et al, 1978), or adrenal cortical hormones (Halliday 1959; Clark 1959). 
The healthy adult mammalian small intestinal wall is thus relatively impermeable to 
large protein and carbohydrate molecules (Chadwick 1977b). Tight (occluding) 
junctions prevent the passage of whole protein and other potentially antigenic 
macromolecules paracellularly, and absorption through the gut wall is dependant on 
prior enzymatic degradation of any macromolecules. Small quantities of 
macromolecules are, however, absorbed through the healthy small bowel wall. 
Bockman and Winborn (1966) in studies with ligated loops of hamster small bowel, 
demonstrated the presence of ferritin in the intestinal absorptive cells following 
intraluminal administration. Uptake of endotoxin in rabbits (Ravin et al, 1960), and 
bacteria in dogs (Schatten 1954) and humans (Schatten et al, 1955) have also been 
found. Horse radish peroxidase (HRP) is a water soluble macromolecule with a 
molecular weight of 40000 and a diameter of 5nm. The recovery of trace amounts of 
this substance in the serum following direct instillation in the rat jejunum represented 
the first demonstration of a macromolecular presence between the intestinal absorptive 
cells and their subsequent quantitation in the mesenteric lymph and portal blood 
systems (Warshaw et al, 1971) . 
There is evidence that alternative routes of uptake exist for larger antigenic molecules, 
as opposed to smaller sized ones. Studies , using Polyethylene Glycol 600 as the probe 
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marker, have shown permeation (at size dependant rates), across the bowel wall 
independent of the latters permeability to larger proteins such as ovalbumin 
(mw=43000), and bovine serum albumin (mw=69000) (Westrom et al, 1984b). This 
would suggest an alternative route of permeation for these macromolecules in the 
healthy bowel. Indeed, recent evidence suggests that, while this occurs by membrane 
bound vesicles and pinocytosis in certain mammals (Walker et al, 1972), it is 
associated, in man, with highly developed 'M' cells associated with lymphoid follicles 
(Colony and Neutra, 1985; Keljo et al, 1985). 
The quantity of macromolecules which pass through the adult mammalian bowel wall 
is, under normal circumstances, relatively small and, generally, of no importance 
physiologically, being cleared by the immune system. The barrier function of the 
healthy bowel is dependent on various factors including an absence of inflammation and 
ulceration (Worthington and Syrotuck, 1976; Grusky and Cooke, 1955). Any 
circumstance which alters the physical or functional integrity of the bowel mucosa may, 
however, lead to an increased permeation of macromolecules across the wall and into 
the intestinal blood stream (Worthington and Syrotuck, 1976). 
PERMEABILITY IN THE DISEASED INTESTINE 
A variety of agents can affect the functional and anatomical integrity of the small bowel 
wall. The permeability of the small intestinal mucosa to various probes is known to be 
affected by bile salts in rabbits (Chadwick et al 1979), guinea pigs (Talbot et al, 1984), 
and rats (Hollander et al, 1989). In man , too, bile acids have been shown to affect 
both the small (Budillon et al, 1980) and large bowel mucosal permeability (Chadwick 
et al, 1977b). Parasitic infestations in rats have also been shown to result in an 
increased permeability to larger antigenic protein molecules (Cobden et al, 1979; Bloch 
et al, 1979). 
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Although naturally occurring detergents like lysolecithin and lyso-phosphatidylcholine 
have also been shown to increase the permeability of the rat (Tagesson et al 1985; 
Bolin et al 1981) and guinea pig small bowel (Talbot et al, 1984) to macromolecules, 
this has not been found with cetrimide, another detergent (Turner et al, 1988). These 
differences may reflect differences in bowel regions studied or the nature of the insult 
on the bowel. 
Diffusion of large molecules across the small intestinal mucosa of children has been 
shown to be greater in damaged or abnormal bowel mucosa when compared to normal 
small bowel mucosa (Jackson et al, 1982). The epithelial cell turnover rate is greater 
in abnormal mucosa and in this in vitro histopathological study, using ruthenium red 
(mw= 1000) as the marker, the number of damaged and non-viable enterocytes 
penetrated was found to be greater in the abnormal mucosa. The degree of penetration 
was also independent of morphological evidence of any damage. Moreover, a large 
degree of penetration by horse radish peroxidase (mw =40000) was also found in the 
abnormal mucosa. This may reflect a greater proportion of abnormal mucosal 
enterocytes permeable to antigenic sized molecules and thus a greater potential for 
passive diffusion in the abnormal intestine. 
While the mechanism of an increased bowel permeability to large protein antigens may 
be related to the possible breakdown in the junctional complexes between epithelial 
cells lining the villi, an altered histology has not been a uniform finding. An increased 
small bowel permeability to horseradish peroxidase has been documented in the absence 
of morphological evidence of mucosa! damage in guinea pigs, following exposure to 
lysolecithicin (Talbot et al, 1984) . The altered bowel permeability associated with bile 
acids, alcohol, parasitic infestations, radiation damage and certain drugs, however, is 
accompanied by histological damage (Talbot et al , 1984;Bloch et al, 1979; Walker and 
Porvaznik, 1978; Erikson et al, 1987). Nadia and co-workers studied the acute affects 
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of EDTA, tetracycline and sodium laurylsulfate on the rat small bowel and found 
varying degrees of histological damage (Nadia et al, 1972). 
It would seem that any altered permeability is dependent not only on the physical 
characteristics of the agent involved but, possibly, also on the environment in which it 
acts. Laker and Menzies (1977) found that the fraction of lactulose excreted in the 
urine of healthy subjects following the ingestion of a lactulose-containing solution, 
increases if it is made sufficiently hypertonic. Udopihille (1974) independently found 
evidence to suggest that the site of this altered permeability was in the small intestine. 
It is probable that hypertonicity per se alters permeability. Morphological alterations in 
the small bowel mucosa have been noted immediately following the application of the 
hypertonic solution (Norris 1973). Evidence would suggest that changes in 
permeability induced by a hypertonic environment are reversible (Laker and Menzies, 
1977; Norris 1973). 
An increased intestinal permeability to small sized molecules has also been found in 
abnormal small bowel. Love (1969), in early experiments in rabbits , demonstrated an 
increased small intestinal permeability to mannitol , erythritol , urea and sodium 
chloride, following infection with cholera organisms. Whether this was as a result of a 
direct effect on the lining cells, or as a result of changes in the local circulation is not 
clear. 
In contrast, however, Rohde and Chen (1972) found that, while canine jejunal 
permeability to 14C-urea and 3H-arabinose was unchanged following experimentally 
induced cholera, administration of the drug amphotericin B, resulted in altered 
membrane permeability and selectivity to these smaller molecules. The differences 
between these studies of intestinal permeability , may be due to differences in the 
sensitivity of the techniques employed, or nonspecific changes that occur in ligated and 
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distended intestinal loops (Scherer et al, 1974). 
The available data supports a concept of different routes of permeation across the small 
intestinal mucosa for different sized molecules. Small molecules, about 0.4nm in 
diameter, permeate through water filled pores in the cell membrane and absorption is 
related to mucosa! surface area. The larger macromolecules, greater than 0.4nm in 
diameter, either diffuse across extracellular pathways between cells or they are taken up 
by a process of endocytosis. In these instances, any increased absorption is related to 
mucosa! or epithelial damage, 
Since the mechanisms of permeation for large and smaller sized molecules would 
appear to differ, the question arises whether changes in permeability to smaller sized 
molecules reflect and parallel alterations in permeability to larger sized molecules. 
Turner et al (1988) found an altered permeability to macromolecules and the sugar 
probes lactulose and rhamnose in rats experiencing hypersensitivity reactions but no 
correlation between the permeability to large proteins (mw 45000) and that of the 
smaller carbohydrate probes (mw 400) was found. In contrast, however, Ramage et al 
(1988) found that an increased permeability to 51 cr-EDTA (mw=360) correlated 
strongly with an increased permeability to ovalbumin (mw =45000) in a study in rats 
that had been infected with Nippostrongylus brasiliensis. The difference between these 
two studies may reflect either different pathways of uptake for carbohydrates and 
EDTA, or a different mechanism of damage when parasitically and immunologically 
induced. 
The concept of an association between the permeation of a potentially antigenic 
macromolecule across the small bowel wall, and the subsequent initiation of a disease 
process was first mooted in 1958 by May et al with the Clostridium botulinum toxin A. 
Similar associations have also been noted with the Cholera toxin in animals (Kao et al, 
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1970; Serebro et al , 1968) and in man (Springer and Horton , 1969). An association of 
leukopenia and an altered intestinal permeability with an increased radiation induced-
sensitivity to endotoxin has also been documented (Walker and Porvaznik, 1978). 
CROHN' S DISEASE 
Crohn's disease is a non-specific inflammatory disease of the gastrointestinal tract and 
is considered to be a generalised gastrointestinal disorder, affecting predominantly the 
small intestine. The disorder is characterised by the presence of ulcerative lesions in 
the bowel wall as well as extraintestinal manifestations such as joint, skin and ocular 
lesions. In Crohn' s disease, the bowel mucosa! ulceration is interspersed with normal 
intervening mucosa, giving rise to characteristic so called "skip lesions" . Clinically, 
the condition is characterised by relapsing episodes of abdominal pain , accompanied at 
times by diarrhoea. 
Treatment remains an often vexing problem, with medical therapy the mainstay of 
treatment. Treatment options here also include dietary manipulation, steroid therapy 
and powerful immunosuppressive agents . Surgery is currently reserved for those 
patients with surgically remediable indications or complications. 
It should be stressed , however , that treatment is at best either symptomatic or 
palliative. The etiology and pathogenesis of Crohn' s disease remains unknown, and 
treatment is thus seldom , if ever, curative. 
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The possibility of a multifactorial etiology can not be excluded. Factors that have been 
implicated in the causation of the disease include: 
1. Genetic 
2. Dietary 
3. Infective (bacterial or viral) 
4. Immunological 
5. Environmental (smoking, external agents) 
1. Genetic 
Chromosomal abnormalities have yet to be demonstrated in Crohn' s disease and the 
disorder is not currently considered to be genetically inherited. Multiple familial 
occurrences have, however, been documented in patients with inflammatory bowel 
disease (Farmer et al , 1980)(Tysk et al , 1988). 
2. Diet 
The role of diet in inflammatory bowel disease remains controversial. A large number 
of different food additives are present in a wide range of processed foodstuffs and there 
is evidence to suggest that the former may be an important factor. Carrageenans, 
which are found in various foods , have been implicated in the pathogenesis of colitis in 
guinea pigs (Watt and Marcus , 1975). In Crohn's patients a good clinical response to 
dietary manipulation and an elemental diet (O'Morain et al, 1984; Kushner et al, 1986) 
is further evidence for a dietary role. Dietary modifications of carbohydrate and fibre 
have, however, failed to alter the course of Crohn' s disease (Ritchie et al , 1986). 
3. Infective 
Bacterial cultures of gut contents of patients with inflammatory bowel disease remain 
inconclusive for an infective aetiology. Bacterial overgrowth , however, seems to be a 
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characteristic feature of Crohn' s disease, along with high serum antibody titres to 
several anaerobes (Van der Merwe 1980). While a report of the isolation of an atypical 
mycobacterium from biopsy specimens from subjects with Crohn' s disease, evoked 
much interest, (Hampson et al, 1988), this mycobacterium could only be isolated from 
a minority of patients , and specificity for Crohn' s disease is also not proven. Evidence 
for a viral aetiology is not any clearer. Observations of granulomatous lesions in 
animals, following injection of homogenates of bowel or mesenteric lymphnodes from 
patients with Crohn' s disease, have not been confirmed (Cave et al , 1977). Thus, 
while the infective theory is an attractive one, knowledge of the role of the gut flora, if 
any, in inflammatory disease remains obscure. 
4. Immunological 
A correlation between some of the extra-intestinal manifestations of Crohn' s disease 
and circulating immune complexes isolated from patient sera has been noted (Jewell et 
al , 1972; Nielsen et al , 1978a & b) . It is possible that these immune complexes are the 
direct mechanism of tissue injury. The relationship between mechanisms of 
inflammatory changes and diet may also be on the basis of food allergy or 
hypersensitivity to any , or all , food components. In terms of the food hypersensitivity 
hypothesis, the continued uptake of fragments of food proteins (albeit in minute 
quantities) , may lead to sensitisation and a mucosal reaction on subsequent ingestion of 
the offending food (Bloch et al , 1988). Some investigators have found a raised 
antibody titre to milk proteins in patients with ulcerative colitis (Taylor and Truelove, 
1961; Taylor et al, 1964). This has, however, not been a universal finding (Jewell and 
Truelove, 1972; Sewell et al , 1963; Dudek et al , 1965) , and a poor correlation between 
the two different methods used by the various investigators has also been reported 
(Steele et al , 1964) . Although inflammatory bowel disease has been associated with 
other immunologically mediated conditions, and a favourable clinical response is seen 
after corticosteroid therapy, there is currently no convincing evidence of an immune 
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defect in the mucosal immune system of these patients (Elson 1988). 
5. Environmental 
While an association between inflammatory bowel disease and smoking has been noted 
and consistently reported, no explanation of its mechanism is forthcoming. A recent 
study found that smoking doubled the risk of acquiring Crohn's disease (Lindberg et al, 
1988). 
INTESTINAL PERMEABILITY AND CROHN'S DISEASE 
There is a substantial body of evidence linking an altered intestinal permeability with 
the pathogenesis of inflammatory bowel disease (Olaison et al, 1990). 
Whether the altered intestinal permeability is a primary or secondary phenomenon to 
the inflammatory changes, is not clear at present. The demonstration, in one study, of 
an increased small bowel permeability to Polyethyelene glycol 400 in healthy first 
degree relatives of patients with inflammatory bowel disease (Hollander et al, 1986), 
suggests that a permeability defect could indeed be a primary genetic phenomenon. In 
addition, the increased anticolon antibody titres noted previously in healthy first degree 
relatives of Crohn 's patients, also implicates intestinal mucosal damage and an 
immunological response as the primary mechanism . 
Crohn' s disease is predominantly a disease of Western civilisation and Western diets. 
The latter is characterised by a conspicuous lack of fibre and this may also thus play a 
role in promoting an altered permeability of the small intestine. Bran has been shown 
to have a protective influence on the permeability-altering effects of bile acids (Gyory 
and Chang, 1983). In a recent study, Shiau and Chang (1986) found that rats fed a 
high fibre diet demonstrated a decreased intestinal permeability to the marker phenol 
red, when compared with rats that were fed a fibre free diet. While the mechanisms 
are not clear, protection could relate to the production of mucin , an important 
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permeability barrier of the large bowel wall. Studies have shown an increased enzyme 
mucinase activity following fibre free diets (Shiau and Chang 1983). High fibre diets 
and a subsequent decreased mucinase producing bacterial population may thus also be 
the mechanism of the known protective role of the former, especially in relation to 
colonic carcinogenesis. Surface active food additives, (for example polyoxyethylene 
(20), sorbitan monostearate and sorbitan mono-oleate) which are also very prevalent in 
Western diets have been shown in rats to increase the permeability of the small bowel 
mucosa (Tagesson and Edling, 1984a). It has been hypothesised that inhibition of 
intestinal phospholipase activity by food additives and a resultant decrease m 
prostaglandins may be the mechanism. While the protective role of prostaglandins in 
the human stomach is well established (Hawkey and Rampton, 1985), it is only recently 
that this role has been found to extend to the small intestine. In a functional and 
morphological analysis of rat jejunum, using mannitol as the probe, pretreatment with 
16, 16-Dimethyl prostaglandin ~ was found to decrease the mucosa! injury caused by 
the bile acid chenodeoxycholate (Erikson et al , 1987). 
Patients with Crohn' s disease have also been noted to have decreased bowel luminal 
concentrations of lysophospholipase, an enzyme thought to prevent the accumulation of 
lysolecithin, a naturally occurring detergent (Bolin et al , 1984). As noted previously, 
certain detergents have been associated with an increased bowel permeability. In 
genetically susceptible individuals detergents may thus act as the external agent 
required to precipitate an immunological inflammatory reaction , via an altered bowel 
permeability . 
TOXICITY OF POLYETHYLENE GLYCOL 400 
The Polyethylene glycols are polymers of ethylene oxide and between molecular 
weights 200-600, are completely water soluble (Cox 1979). They vary in consistency 
from waxy solids to liquids , and are extensively used in the food , cosmetic and 
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pharmaceutical industries. The metabolism and toxicity profile of ethylene glycol has 
been well documented (Parry and Wallach 1974; Cadnapaphornechai et al, 1981). 
Excretion of polyethylene glycol 400 is in a 2: 1 ratio, urine to stool following oral 
ingestion. Approximately 55 % of an oral ingested dose of PEG 400 is recovered in the 
urine over a 48 hour period (Chadwick et al , 1977a). Of this, 82 % is excreted in the 
first 12 hours. While doubts have recently been expressed concerning potential toxicity 
and the possible topical absorption of large doses of PEG 400 from PEG containing 
burn creams (Bruns et al , 1982; FDA drug bulletin 1982; Herold et al, 1982), no 
causal relationship between burn creams and toxicity has yet been established (FDA 
Drug bull 1982). The reports (Bruns et al, 1982; Herold et al , 1982) are, however, 
flawed as no serum or urinary levels of PEG are given. The possibility of 
contamination of the creams by microorganisms with subsequent formation of ethylene 
glycol, has been mooted. Golytely , which contains PEG 3350 (formerly PEG 4000), is 
commonly used as a saline lavage prior to colonoscopic examination of the large 
bowel. Despite its use for more than 50 years, there are no reports of any side effects 
of this PEG when administered orally to patients with normal or diseased bowels 
(Goldman and Reichelderfer, 1982; DiPalma and Brady 1989; Brady et al, 1986). 
The average dose of PEG obtained from 4 litres of Golytely is greater than 240g 
(Lifton 1984) . No data is currently available for the LD50 of PEG 400 in man or 
animals. The LD50 of PEG 4000 in rats is greater than 50g/kg (Smyth et al, 1955). 
This is equivalent to 3500g in a 70kg man and is infinitely greater than the considerably 
smaller total oral dose of 5.6 grams given in the present study . The mean administered 
dose of PEG in Golytely is 2.0g/kg, and clinical studies have found it to be a safe and 
nontoxic method of colon cleansing with minimal absorption of polyethylene glycol 
(DiPalma et al , 1983 ; DiPalma and Brady, 1989; Brady et al, 1986; DiPiro et al, 
1986). In addition, no side effects have been reported in studies with oral ingestion of 
20 grams of PEG 400 (Chadwick et al, 1977a). 
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In view of the above data, it was felt that polyethylene glycol 400 would be a safe, 
non-toxic oral probe for use in permeability studies of the bowel. 
24 
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PURPOSE OF STUDY 
The pathogenesis of Crohn' s disease may involve interaction between host, 
immunological responses and external agents (Shorter et al, 1972). In terms of this 
hypothesis, the external agent is an antigen of some type (bacterial, viral or dietary), 
which gains entry through the bowel wall in association with an altered gut mucosal 
permeability. The subsequent autoimmune reaction then precipitates the characteristic 
intestinal lesions seen macroscopically. In the presence of granulocytes, an increase in 
intestinal permeability to endotoxin, whether via discontinuities in the tight junctions or 
direct penetration through the lining cells, may lead to stimulation of the inflammatory 
response (Walker and Porvaznik, 1978). 
A study by Hollander (1986) suggested a permeability defect in family members of 
patients with Crohn 's Disease. The present study was undertaken in order to: 
a) Validate the previously used methodology for determing the concentration of PEG 
400 in urine. 
b) Establish, rn a larger group of subjects, the presence or absence of an altered 
intestinal permeability to PEG 400. 
c) Examine the effect on intestinal permeability in Crohn 's patients of: sex, age, extent 
of disease, effect of bowel resection, disease activity and treatment. 
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CHAPTER TWO: STATISTICAL ANALYSIS 
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Data are presented as urinary recovery of the orally administered dose of PEG 400, 
expressed as a percentage. Because results are expressed as a percentage, normal 
distribution cannot be assumed and results are expressed as median and range. As the 
data do not conform to Gaussian distribution , non-parametric tests of analysis have 
been used. Statistical differences between more than 2 groups were analysed using 
Kruskal-Wallis one way analysis of variance. The Mann-Witney test was used to 
calculate statistical significance when there were only 2 comparisons. 
The Coefficient of Variation (CY) was calculated using the following formula: 
Standard Deviation x 100 
Mean 
The standard error of measurement (SEM) is calculated from the following formula: 
.JEw2/2n 
where w = difference between two results 
and n = the number of duplicate samples 
Results of comparisons were considered significant if p < 0.05. 
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CHAPTER THREE: CHOICE OF PROBE 
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Various probes have been used to examine small bowel permeability in the human. 
These include iron (Loehry et al, 1973) , 51 cr-EDTA (Peled et al, 1985 ; Ainsworth et 
al, 1989; Bjarnason et al, 1983), labelled-DTPA (Casellas et al, 1986; Resnik et al, 
1990) , the carbohydrates, lactulose and mannitol (Andre et al, 198; Cobden et al, 
1978; Ukabam et al, 1983; Murphy et al, 1989) , PEG 1000 (Tagesson et al, 1983; 
Olaison et al, 1987; Olaison et al, 1989), PEG 900 (Katz et al, 1987), PEG 600 
(Olaison et al, 1988; Olaison et al, 1989) and PEG 400 (Hollander et al, 1986; Jenkins 
et al, 1986; Magnusson et al, 1983). Using these different probes, an altered small 
bowel permeability has been demonstrated in a variety of disease and physiological 
states in man eg. parasitic and bacterial infestations (Serrander et al, 1984; Serrander et 
al, 1986; Weaver et al , 1985; Bjarnason et al, 1985) , atopic eczema (Bjarnason et al, 
1985b; Jackson et al, 1981), coeliac disease (Bjarnason and Peters , 1984; Pearson et al, 
1982), post-alcohol ingestion (Robinson et al, 1981) , inflammatory bowel disease 
(Ukabam et al, 1983 ; Sanderson et al, 1987) , and schizophrenia (Wood et al, 1987). 
The methodology used in permeability tests of the small bowel all involves oral 
ingestion of a probe and subsequent recovery and quantitation of the probe in a timed 
urine collection. Recovery of the probe is expressed as a percentage of the orally 
ingested dose. 
Chromium labelled ethylenediaminetetraacetic acid c51 Cr-EDT A) is a highly stable, 
water soluble, polar molecule with an average molecular weight of 380 daltons and no 
affinity for any particular organ. The normal human colon has, however, been found 
to absorb significant amounts of orally administered 
51 cr-EDTA in the absence of any 
intestinal inflammation (Ramage et al, 1987; Elia et al, 1987). As a single marker, 
urinary quantitation can be affected by incomplete urine collection and gastric 
emptying. It is apparently poorly abso rbed from the gut lumen , its route of uptake 
being thought to be via the paracellular junctions. 
51 cr-EDTA has been extensively used as a marker of intestinal permeability, despite 
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the finding that 5lcr-EDTA per se is associated with an altered bowel permeability 
(Windsor and Cronheim, 1961). The mechanism, though unclear, may be related to 
the chelation of calcium with a resultant weakening of the gut intercellular tight cell 
junctions (Windsor and Cronheim, 1961; Nadia et al, 1972). Indeed, EDTA has also 
been used as a promoter to aid in the absorption of sulphanilic acid in the rat jejunum 
(Yamashita et al , 1985). 
Technetium99M_diethylenetriamine pentacetate (99MoTPA) has also been used as a 
probe of intestinal permeability. Its structure and clearance are similar to those of 
51cr-EDTA (O'Morain et al , 1984). Indeed , studies by O'Morain et al and Resnick et 
al ( 1990) have found a positive correlation between these two probes when ingested 
simultaneously. In contrast to 5 I Cr-EDT A, a considerably smaller oral dose of DTPA 
can be given. While the use of both probes involves radioactivity, it is in small and 
thus relatively safe quantities. 
The double-sugar test involves ingestion of two sugars that have slightly different 
routes of permeation. The polar disaccharide molecules lactulose (mw=342, 
d=0.54nm) and cellobiose (mw=342 , d=0.52nm) are restricted transmucosally, and 
are thought to cross the intestinal mucosa passively , through channels associated with 
the tight junctional complexes between cells (intercellularly) (Menzies et al 1979; 
Wheeler et al, 1978). In contrast , the slightly smaller, relatively inert mannitol 
(mw= 182, d=0.4nm) and rhamnose (mw= 164, d=0.4nm), are thought to permeate 
directly through the cell membrane (transcellularly) by means of water filled pores 
(Menzies et al , 1979). Absorption of these markers would seem to be dependent on 
molecular volume, rather than molecular mass, molecular radius or area (Elia et al, 
1987). 
The carbohydrates mannitol, lactulose, cellobiose and rhamnose have been extensively 
used as markers of altered intestinal permeability. They are all of a similar size and, 
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following ingestion of an oral dose, are fully excreted within 6 hours via the kidneys. 
A wider separation of normal and abnormal function is obtained when the percentage 
urinary recovery is expressed as a ratio than if the sugars are individually and 
separately considered. In addition, when expressed as ratio, absorption and excretion is 
less dependent on variables like gastric emptying, intestinal transit time and renal 
disease (Ukabam et al, 1983). The presence of intestinal disease affects the permeation 
of these markers differently. The passage of the transcellularly transported probes (like 
mannitol) seems to be reduced with villi shortening and loss of intestinal surface area. 
The carbohydrate probes transported paracellularly (like lactulose) seem to reflect 
actual morphological mucosa! damage (Ukabam et al, 1983) . For example, in patients 
with coeliac disease, the permeability to lactulose is increased, while that of mannitol 
and rhamnose is decreased (Menzies et al, 1979; Cobden et al, 1978). 
A large number of healthy, as well as clinically ill , elderly people may have a 
significant degree of bacteruria, however, and urinary infection has recently been 
shown to possibly invalidate this double sugar test (Milnes et al, 1988). 
Polyethylene glycols are hydrophilic, lipophilic polymers of ethylene glycol. They are 
mixtures of varying molecular weights and consist of populations of elongated 
molecules of differing sizes. PEG 400 is a colourless liquid consisting of nine separate 
polymeric units , with molecular weights ranging from 242 to 594 daltons. As the 
average weight is 400 it is called PEG 400. 
Assessment of intestinal permeability involves oral ingestion of a probe and subsequent 
urinary quantitation in a given time period. Results , however, relate also to other 
factors such as gastric emptying, intestinal luminal dilution and renal function. The 
advantage of polyethylene glycol preparations in permeability studies is that, unlike a 
single test substance, they consist of a spectrum of molecular sizes. Absorption of the 
different molecular species can thus be expressed as a ratio. Permeability may thus be 
assessed independently of gastric emptying, intestinal transit and renal clearance. 
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Consequently , a comparison of ratios of absorption of the species is a reliable index of 
permeability . 
While the site of maximal absorption of PEG 400 is not known, the absorption of the 
latter does seem to be independent of food intake (Chadwick et al, 1977a). 
Initially, PEG 400 could be qualitatively assayed only by gas chromatography but a 
new method of analysis using High Pressure Liquid Chromatography (Delahunty and 
Hollander, 1986) has recently been described. 
The selection of a probe is a contentious subject as each has its own advantages and 
disadvantages. This was addressed by Chadwick et al ( 1977a) when he published a list 
of properties the ideal permeability probe shou ld possess. 
a. It should be a non-toxic, biologically non-degradable substance 
b. It should be a mixture of varying sized compounds which show decreasing 
mucosa! transport with increasing molecular size. 
c. Transport of each molecular species should follow first order kinetics. 
d. The probe should not influence intestinal motility. 
e. The probe should not be metabolised after absorption. 
f. The probe should be able to be measured with precision, sensitivity, accuracy 
and ease. 
g. The marker should be rapidly and completely excreted m unne, allowing 
quantitation , and thus be a measure of absorption. 
The advantages of PEG 400 are that it is non-toxic and consists of a variety of differing 
molecular weight molecules that permit comparisons. The lack of radioactivity is 
important to subject and investigator alike. Methods for measurement have been 
established. Furthermore, the work that instigated this study was one in which PEG 
400 was used to detect changes in permeability in family members of Crohn's patients. 
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CHAPTER FOUR: MATERIAL AND ANALYTICAL METHODS 
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CLINICAL MATERIAL 
All subjects gave informed consent and the protocol was approved by the Ethics 
Committee of the University of Cape Town. 
The Crohn's group: Forty five patients in whom the diagnosis of Crohn's disease had 
been clinically, endoscopically and radiologically established, and who were attending 
the outpatient department of the Gastrointestinal Clinic, were included in the study. 
Details of age and sex are shown in Table 1. 
The family group: Twenty first degree relatives of 14 patients with Crohn 's disease 
were studied. Six patients had two first degree relatives studied. All relatives were in 
good health and had no evidence of any gastrointestinal disease, either on history or 
examination. There was also no history of any drug or alcohol ingestion in this group 
in the 48 hour period immediately preceding the test. Their age and sex distribution 
are shown in Table 1. 
The control group: This group consisted of 31 healthy subjects (Table 1). There were 
6 males and 25 females. The youngest volunteer was 24 years old , and the oldest 72 
years of age. All the control subjects were healthy, with no evidence, either on history 
or examination of any bowel disease. There was no history of ingestion of any drugs 
(specifically non-steroidal drugs) or alcohol in the 48 hours immediately preceding the 
test. The controls were of a similar socioeconomic background to the other groups 
studied. 






















(range) n (range) 
(20-72) 26 (19-60) 
(13-55) 12 (11-70) 
(30-53) 25 (24-72) 
INDICES OF DISEASE ACTIVITY IN PATIENTS WITH CROHN'S DISEASE 
All patients with Crohn' s disease underwent a clinical examination and had blood 
drawn for routine biochemical and haematological analysis. Using this data, two 
indices were calculated and used in the present study as reflections of inflammatory 
disease activity in the patient group viz. the van Hees index and the National 
Cooperative Crohn's Disease Index (NCCD). The van Rees activity index is based on 
the data derived from 63 patients (Van Rees et al, 1980). The following nine variables 
were found to correlate to the overall evaluation: serum albumin, erythrocyte 
sedimentation rate (ESR), sex , temperature , abdominal mass , body weight related to 
length, stool consistency, bowel resection and extraintestinal symptoms related to 
Crohn's disease. Index values below 100 are indicative of inactivity , values between 
100 and 150 are associated with slight inflammatory activity, values between 150 and 
210 as indicating moderate activity and values above 210 as indicating severe to very 
severe inflammation. The NCCD index is based on data collected prospectively from 
112 patients with Crohn' s disease (Best et al, 1976). It makes use of the following 8 
variables: the number of liquid and soft stools in one week , the sum of 7 daily 
abdominal pain ratings, the sum of 7 daily ratings of general well-being, symptoms or 
signs related to Crohn' s disease, use of lomotil or opiates for diarrhoea, presence of an 
abdominal mass , the haematocrit and body weight. Index values below 150 are 
associated with inactive inflammatory disease, while values above 150 have are 
regarded to be indicative of active inflammation. 
SAMPLE COLLECTION. 
After an overnight fast , subjects ingested 5.6 grams of PEG 400 with 200 ml of water. 
During the following 6 hours , the oral intake of water was unlimited , but no food was 
allowed. Any urine passed during this 6 hour period was collected, together with the 
urine passed at the end of the 6 hours. The total urine volume passed by each subject 




1) Freeze Dryer (Thermovac, Thermovac Corporation, USA) 
2) Nitrogen Gas Manifold. 
3) The HPLC system consisted of: 
a) Chromatograph (model SP 8800, SpectraPhysics, San Jose, CA , USA). 
b) Injection system (Rheodyne, Cotati, CA). 
c) Interchangeable 20 and 200 microlitre sample loops. 
d) Reversed phase column (styrene divinylbenzene column PLRP-S, 25cm 
(length), 4.6mm (id), Polymer Laboratories , Amherst MA , USA). 
e) Refractive index detector (SpectraPhysics model SP 8430) f) Integrating 
recorder (SpectraPhysics model SP 4290). 
(II) Chemicals. 
Chloroform - Analar Grade 
Methanol - HPLC Grade (Baxter Healthcare Corporation) 
Deionized water - Milli-Q system Millipore Ltd, South Africa. 
Polyethylene Glycol 400 - Lot 120F/0189, Sigma Chemical Corporation St Louis MO, 
USA. 
HPLC TECHNIQUE 
An isocratic mobile phase (equal volumes of methanol and water) was used to elute the 
PEG 400 from the column at a flow rate of lml/min. The mobile phase was degassed 
by continuous sparging with Helium. 
PREPARATION AND ANALYSIS OF STANDARDS . 
Standards were prepared by dissolving PEG 400 in water at concentrations of 0.2, 0.4 , 
0.8, and 1.6 grams per litre. Each standard was analysed in duplicate by injecting 20µ.l 
aliquots onto the chromatograph. A standard curve of total area for all peaks versus 
PEG 400 concentration , was plotted for each analytical run. A linear standard curve 
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was obtained for concentrations varying from 0.2- l.6g/l (Fig 1) . Nine peaks were 
readily separated and detected , within twenty minutes of injection , (Fig 2). These 
peaks corresponded , on the basis of retention times , to PEG 400-species with a 
molecular weight from 286-638 (Delahunty and Hollander , 1986). The six main 
components constituted about 90% of the total and could be measured with an 
acceptable degree of analytical precision throughout the range of concentrations (Table 
2). 
Table 2. Precision of PEG 400 Assay 
Peak number I II III IV V VI 
PEG 400 cone (g/1) CY % for various PEG fractions 
0. 2 8.8 8.2 6.4 3.3 6.4 6.7 
0.4 8.5 3.4 4.5 5.2 6.1 6.9 
0.6 3.8 2.7 2.6 6.4 7. 2 7.0 
0.8 4.0 3.8 3.0 5.0 4.7 5.0 
1.6 1.3 1.5 1.5 1.9 2.2 1.4 
PREPARATION AND ANALYSIS OF URINE SAMPLES 
EXTRACTION METHOD 
Initially the method of Delahunty and Hollander (1986) was used in analysis of the 
urinary PEG 400. Urine was thawed at room temperature. Duplicate 10ml aliquots of 
urine were lyophilized in a 100ml stoppered flask overnight. PEG 400 was extracted 
from the freeze-dried urine by addition of 10 ml of chloroform , followed by 10 minutes 
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Fig. 1. Standard curve obtained by plotting total area of all peaks (AUC) against 
concentration of PEG 400. 
Mean + SD (10 separate analyses) is shown at each concentration. 
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Fig.2. Typical HPLC chromatogram of PEG 400 (0.8g/L). 
Retention times (minutes) are shown for each of the six peaks that were 
individually analyzed. 
and evaporated to dryness under a stream of nitrogen. Two millilitres of the mobile 
phase for HPLC (methanol:water, 1: 1, v:v) were used to reconstitute the sample. The 
sample was then aspirated with a 5ml disposable syringe and filtered through a 0.22 
micron filter (Millipore Ltd , South Africa). Twenty microlitres of the filtrate was 
injected onto the chromatograph. HPLC analysi s was performed in duplicate for each 
sample. The concentration of PEG 400 in the urine was obtained by reading off the 
standard graph . Results are expressed as the percentage of the ingested dose which is 
recovered in urine. 
Recovery of PEG 400 in urine 
Recovery of PEG 400 in urine was determined by the addition of PEG 400 to aliquots 
of pooled normal urine, to give concentrations varying from 0.2 to 1.6 grams per litre 
(Table 3). 
Table 3. Recovery of added PEG 400 
PEG 400 added (g/1) 0 .2 0.4 0.8 1.6 
% recovered (Mean)(n =7) 86.2 88.4 91.6 90.4 
(SD) 4.1 5.3 4.6 5.7 
Recovery varied from 82. 1 % to 96. 2 % . 
Reproducibility 
Reproducibility was determined by including aliquots of a single urine specimen in 10 
analytical runs , performed on 10 separate days . The Coefficient of Variation (CV) was 
found to be 13.3 % . 
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Limit of detection 
The lower limit of detection in a urine sample was found to be at a concentration of 
0.5g/L 
The above extraction method was used to analyse PEG 400 excretion in patients with 
Crohn 's disease, their healthy relatives and a group of controls (Rutten berg et al , 
1989). A wide scatter within , and no difference between , any of the groups were 
found. The results were also characterised by poor reproducibility (CV= 13 % ) and 
variable recovery (82-96% ). The extraction method involves the numerous steps:-
pipetting of a 10ml aliquot of urine, lyophilisation overnight, extraction with 
chloroform, evaporation under a stream of nitrogen and reconstitution of the sample 
prior to injection onto the HPLC column. Variable loss of sample can occur at any one 
or several of these steps. Technical imperfections in this extractiion method might 
explain the wide scatter and lack of differences and a new more accurate method of 
direct injection HPLC was therefore developed. 
DIRECT INJECTION METHOD 
Urine specimens were thawed at room temperature and analysis performed in duplicate 
for each sample. Two millilitres of urine was diluted with 2ml of deionized water. 
The sample was mixed and , using a 5ml disposable syringe, filtered through a 0.22 
micron filter. Two hundred microlitres of the filtrate was injected onto the 
chromatograph , and analysed in the same manner as the standards. 
The percentage distribution of the six main peaks was similar in standards, PEG 400-
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Homologs of PEG 
Fig.3. Relative abundance of each Mr fraction of PEG 400 as determined by HPLC_ 
The three bars for each fraction correspond to PEG standards, 
PEG-supplemented urines, or urines from subjects 
(left to right, respectively),mean + SD. 
Recovery of PEG 400 in urine 
Polyethylene glycol recovery in urine was determined by the addition of PEG 400 to 
aliquots of pooled normal urine , to give concentrations varying from 0.2 to 1.6 grams 
per litre. A consistently high recovery of added PEG 400 was obtained at 
concentrations from 0.2-l.6g/l (Table 4) . 
Table 4. Recovery of added PEG 400 
PEG 400 added (g/1) 0.2 0.4 0.8 1.6 
% recovered (Mean)(n =9) 97 .2 94 . l 101.8 99.1 
(SD) 3.9 2.7 5.4 5.4 
Reproducibility of method 
The standard error of measurement (SEM) between duplicate determinations was 0.87 
(n = 100). An aliquot of a single urine specimen was included in 10 analytical runs, 
over 10 separate days , to determine the reproducibility of the method. The Coefficient 
of Variation (CV) was found to be 3.3 % . 
Detectability 
The lower limit of detection in a urine sample was at a concentration of 0.05g/l. 
Stability of samples 
The effect of freezing and thawing at -16°c on PEG 400 in urine was examined. Ten 
samples were assayed before and after 3 months storage. The percentage excretion 
initially was 22.3+ 2.1 % and after 3 months 21.5+ 3.1 %. 
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COMPARISON OF THE TWO ANALYTICAL METHODS 
All samples were re-analysed and results obtained with the new "direct injection" 
method were compared with results using the older extraction method of Delahunty and 
Hollander (1986). Both direct injection and extraction methods showed a similar 
percentage distribution of the six main peaks in standards, PEG 400-supplemented 
urine and urine from the subjects studied. The excretion values of PEG 400 for the 
'direct' injection method were generally higher than those obtained with the 
'extraction' method especially at the extreme range of excretory PEG 400 values 
(Figure 4). A significant correlation between the two analytical methods was, 
however, found in the midrange of PEG 400 excretory values. 
The direct injection method was found to have several advantages , when compared to 
the previously described extraction method . The analysis of urine samples using the 
~xtraction method involves several preparative steps, prior to HPLC analysis. Loss of 
sample at any of these stages, with resultant ' underestimation' of PEG 400 in urine is 
therefore a real possibility. This is reflected by a higher recovery of PEG 400 in urine 
using the ' direct' injection method and also possibly the lower interassay Coefficient of 
Variation for the ' direct' method (3.3 % ) , when compared to the 'extraction' method 
(13.3%). 
The lower limit of detection (0.05g/l) obtained using the ' direct ' injection method is 
similar to that found by Chadwick using gas chromatography (Chadwick et al, 1977a). 
It is notably more sensitive than the 0.5g/L for the ' extraction' method. 
Extraction , evaporation and reconstitution are unnecessary and thus a considerable 
saving of time was found with the direct injection method. Dilution and filtration of a 
sample prior to injection takes about 5 minutes and thus analytical time taken is mostly 
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Fig.4. Comparison of PEG 400 excretion (g/6h) in 100 subjects as determined by 
direct injection and extraction methods. 
duplicate analyses may be unnecessary: thus , with the use of an automated sampler, an 
analysis rate well exceeding 60 samples per day is possible. The time taken, however, 
to analyse any sample utilising the extraction technique, is in excess of 12 hours. 
Lyophilisation is a lengthy procedure, but was usually performed overnight. 
Furthermore, the extraction process and evaporation and reconstitution take about 40 
minutes per sample. 
As less sample is needed for analysis usmg the direct injection method, storage 
requirements are less. 
Cost containment is also possible as fewer chemicals and less equipment is needed in 
analysis. The extraction technique involves the use of substantial quantities of 
chloroform for the extraction and nitrogen for evaporation. 
The direct injection technique thus has the advantages of better sensitivity, precision 
and reproducibility. Furthermore, it is more cost-effective in terms of material and 
time. 
REPRODUCIBILITY OF THE PEG-400 ORAL ABSORPTION TEST IN 
INDIVIDUAL SUBJECTS. 
The oral PEG-400 absorption test was repeated m nine subjects at an interval of 5 
months. The test-retest correlation coefficient was 0. 74. The standard error of 
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TEST 1 TEST2 
Fig.5. Reproducibility of the oral PEG 400 test. Values obtained on two separate 
occasions with an interval of 5 months are shown for individual subjects. 
CHAPTER FIVE: RESULTS 
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Statistical analysis of all results showed a non-parametric distribution. Results are 
therefore expressed throughout as median and range. 
The urinary excretion of PEG 400 as a percentage of the ingested dose is shown for all 
three groups in Table 7. There was no correlation between age (r=0.08) and urinary 
PEG 400 excretion within the group with Crohn 's disease, the relatives, or the control 
group (Figure 6). No difference in urinary PEG 400 excretion was found between the 
males and females in all the groups (Tables 5 & 6, Figure 7). Furthermore, there was 
no difference in PEG 400 excretion between either men with Crohn' s disease and 
healthy male controls, or between women with Crohn 's disease and healthy female 
controls. 
Table 5. Urinary PEG 400 recovery in all subjects 
n Age Median% Range 
Crohn's 
Males 19 20-72 23.2 7.6-33.4 
Females 26 19-60 21.5 6.1-39.9 
Family 
Males 8 13-55 22 .9 18 .8-39.9 
Females 12 11-70 23.1 4.8-28.6 
Controls 
Males 6 30-53 24.7 19. 7-39. 7 
Females 25 24-72 25.0 4.5-36.2 










7.6 - 39.9 
















40 • • --... t ... ... I t ..__ ..__ -
30 • ... • ...... AJ,.A ~ •• ... t ... • 1-·· ••• •:-• ~ ... i •• .... 
20 ... • i ·1· •• t ...... • •• • .a .... • 
r • • A 10 I ..... A ... 
A 
0 
CROHN'S RELATIVES CONTROLS 
• MALES 
A FEMALES 
Fig.7. Relationship between gender and urinary PEG 400 excretion in patients with 













The 45 patients with Crohn's disease excreted 21.9% (6.1-39.9%), the 20 relatives 
23.7% (4.9-39.9%) and the 31 controls 25.0%_(4.5-39.7%) (Table 7). A wide scatter 
was evident and excretion for all three groups ranged from 4.55-39.9%. 
Table 7. Urinary PEG 400 recovery 
n Median% Range 
Crohn's 45 21.9 6.1-39 .9 
Family 20 23.7 4.9-39.9 
Controls 31 25.0 4.5-39.7 
No preferential absorption and excretion of individual PEG 400 polymers was found in 
any of the three groups studied (Figure 8). 
On the basis of disease extent patients were further subdivided into groups viz:- those 
with ileal, ileocolonic or colonic disease (Table 8). Disease extent did not influence 
urinary PEG 400 recovery, but the numbers in each group were relatively small. 
Patients with ileal disease excreted 23.8% (7.7-30.6%), those with ileocolonic disease 
22.6% (14.4-33.8 %) and those patients with colonic disease 27.8% (9.5-33.5%). 
Table 8. Urinary PEG 400 recovery in Crohn's patients according to disease 
* extent 
% of ingested dose 
n median range 
Ileal 14 23.8 7.7-30.6 % 
Ileocolonic 9 22.6 14.4-33.8 % 
Colonic 10 27.8 9.5-33.5 % 
Controls 31 25.0 4.5-39.7 % 
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Fig.8. Relative abundance of each Mr fraction of PEG 400 as determined by HPLC. 
The mean and standard deviation are shown 
Twelve patients had undergone previous bowel surgery of varying length (Table 9). 
The median urinary PEG 400 excretion in this group was 18.8 % (8.1-39.9%). While 
no difference in PEG 400 excretion was apparent between this group and the controls 
or the family, a significant difference was found between them and the non-resected 
Crohn 's patients (23.5 % , Quartile Deviation =5. 8 % , 6.1-33.8 % p < 0.02). 
Table 9. Length of bowel resection and urinary PEG 400 recovery 
Length of resection Patient no. % of ingested dose 
Less than 5cm 1 39.9 
2 23.7 
5 to 20cm 3 13.4 
4 19.4 
5 17.2 
6 15 .2 
7 9.4 
> 20cm 8 18.9 
9 8.1 
10 19.0 
The non-resected group of patients was further subdivided according to disease activity 
using the van Hees and NCCD indices (Table 10). Patients with a score of less than 
150 with either index were considered to be well. As adjudged by the van Hees Index, 
10 patients were well. The median PEG 400 excretion in this group was 21.6% (14.2-
39.9%). Twenty nine patients had significant disease activity and their median PEG 
400 excretion was 22.2 % (6.1-33.8 %). On the basis of the NCCD index , 36 patients 
were well and had a median PEG 400 excretion of 22 .7 % (6 . 1-33 .8 %). Four patients 
who were ill excreted a median PEG 400 of 18.4 % (13.5-25.2 %). 
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Table 10. Disease activity and urinary PEG 400 recovery 
% of ingested dose 
Index n Status Median Range 
NCCD 36 Well 22.7 6. 1-33.8 
NCCD 4 Ill 18.4 13.5-25.2 
V.Heese 10 Well 21.6 14.2-39.9 
V.Heese 29 Ill 22.2 6.1-33.8 
The effect of treatment alone (irrespective of clinical disease activity) was examined in 
the non-resected patients. There were 11 in the treatment group and 22 patients off 
treatment (Table 11). Patients on treatment excreted 24.4% (9.5-33.8%) of the 
ingested dose as compared to 23.3% (6.1-33 .5 %) in the untreated group. 
Table 11. The effect of treatment on urinary PEG 400 recovery 
% of ingested dose 
n 
On Medication 11 
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CHAPTER SIX: DISCUSSION 
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CLINICAL PROTOCOL 
The subjects in the study were allowed water only following the ingestion of 
polyethylene glycol 400. This is in accordance with all the other investigators using 
PEG 400. Previous work by Chadwick (1977a) using PEG 400, and more recent work 
using PEG 1000, has found no difference in urinary PEG excretion when ingested with 
or without food. In this latter study in 13 volunteers, using PEG 1000 as the probe, the 
protocol included the ingestion of a substantial breakfast consisting of rolls, coffee and 
tea followed some 3 hours later by three open sandwiches (Philipsen 1988). No 
significant difference in the 6 hour urinary PEG recovery was found between the 
fasting and non-fasting subjects. 
In the present study , the dose of PEG 400 was mixed in 200ml of water. An unlimited 
quantity of water was allowed in the subsequent 6 hour urinary collection period. The 
osmolality of the ingested solution was 64 mOsmol (Normal 70-300). While 
hypertonic solutions are known to alter small bowel permeability per se (Norris 1973; 
Laker and Menzies, 1977), the ingested test solution would in any event have been 
diluted subsequently by the luminal bowel fluid . It was considered beyond the scope of 
this study to study the effects of differing osmolalities on the small bowel permeability. 
A six hour urine collection period was chosen so as to permit comparative analysis with 
other investigators. It is highly improbable that a longer period of urine collection 
would have led to different conclusions. Chadwick ( 1977a) examined urinary excretion 
for a 48 hour period immediately after the ingestion of 10g of PEG 400. Twenty six 
percent of the ingested dose was excreted in the first 6 hours , a further 19 % was found 
in the subsequent 6 to 12 hour period , 7.2 % in the 12 to 24 hour period and 3.1 % in 
the 24 to 48 hour collection period. Maxton (1986) examined a 24-hour time sequence 
after oral administration of 1 Og of PEG 400 and found that 16 % of the ingested dose 
was excreted in the 5 hour period following ingestion. In view of the above, it was 
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considered that any extension beyond a 6 hour collection period would not yield any 
significant information. Furthermore, twenty-four hour urine collections are 
cumbersome and subject compliance is a problem. 
The test dose used in the present study was 5. 6 grams. Absorption and excretion of 
PEG 400 polymers is proportional to the ingested dose and therefore follows first order 
kinetics. A larger test dose of PEG 400 would have not have yielded different results. 
In addition, the sensitivity of the direct injection methodology permits oral 
administration of a smaller dose of PEG . Furthermore, a 5. 6 gram dose would also 
mean less possible sequestration of absolute amounts of PEG 400 in the tissues. 
The effect of body mass on PEG 400 urinary excretion was not studied. While 
individual body mass was not measured , no subject was either particularly obese or 
emaciated, and therefore a constant oral dose of 5.6 grams of PEG 400 was used. 
CLINICAL RESULTS 
A large scatter in urinary excretory values was evident in all the groups. This is not 
easily explained. The reproducibility of the method was very good (CV =3.3 % ). 
Consequently , technical and methodological faults and inaccuracies are not likely to be 
responsible for the wide scatter. The standard error due to the intraindividual variation 
was 3.09, while the test-retest reliability coefficient was r=0.74. The latter value 
reflects the results of only nine subjects and a better correlation might be found with a 
larger sample. Alternatively , it may suggest that this scatter may not be biological, but 
rather, probe related, and probably reflects the inherent characteristics of the probe. 
A large intragroup scatter has also been found by other investigators. Indeed, Jenkins 
et al (1986) had a range from 12 . 1 to 35 .9% in their control group. Excretion of PEG 
400 into the urine is not dependent solely on the gut mucosa} permeability, but also its 
space of distribution in the body (Blatzinger et al , 1981) . While data on the latter is 
not readily available, capiJJary filtration may play an important role in sequestration 
50 
into the extravascular space (Tagesson and Sjodahl , 1984) . While the effect of lean 
body mass on urinary PEG 400 recovery was not examined in the present study, all the 
controls were within the normal range of normality . The absolute amount of PEG 400 
sequestrated in the tissues obviously differs from person to person and this may also be 
a contributing factor in the wide scatter. 
A wide scatter has also been found by some investigators using 
51 cr-EDTA. Despite 
differences on a group basis , there was nevertheless, considerable overlap of the results 
for patients and controls in the studies of Peled et al ( 1985) and Ainsworth et al (1989). 
The control group in the study by Peled et al was not homogeneous as all the subjects 
had digestive pathology, albeit not of the small bowel. This may account for the 
considerable overlap with the Crohn' s group. The finding of overlap found by 
Ainsworth et al may, however , reflect individual subject differences and is similar to 
that found in the present study . Overlap in urinary recovery values may also be a 
function of the probe. No overlap with normal control values has been found in 
patients with Crohn's disease using the probe DTPA (O'Morain et al , 1984). 
RELATIONSHIP TO PERMEABILITY OF GENDER 
No relationship was found between the gender of subjects and PEG 400 excretion in 
any of the groups (Table 5 & 6, Figure 7). There was al so no difference in the 6-hour 
urinary PEG 400 excretion between the male patients with Crohn 's disease and the 
control males , or between the Crohn 's females and the control females. These findings 
are in agreement with the findings of Ainsworth et al (1989) using 5lcr-EDTA. 
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RELATIONSHIP TO PERMEABILITY OF AGE 
In the present study, while the youngest subject was 11 years old, the majority were 
mature adults. No correlation was found between age and PEG 400 excretion in any of 
the groups studied (Fig 6). No published data exists on the relationship between age 
and PEG 400 excretion. 
Findings using the similar sized probe 5 lcr-EDTA have not proven any more 
conclusive. While a negative correlation was found between age and urinary 5
1cr-
EDT A recovery by Aabakken ( 1989) no correlation between age and 
51 Cr-EDT A 
excretion could be found by Ainsworth et al ( 1989) . 
There is, however, some evidence that ageing may affect permeability, particularly to 
larger molecules. An increase in bowel permeability to larger sized molecules has 
previously been documented in the neonate as compared to mature animals (Halliday, 
1959; Clark, 1959; Westrom, 1984). As previously discussed, a process of closure 
occurs and the amounts of macromolecules subsequently absorbed through the healthy 
mammalian adult gut wall are insignificant. In a recent in vivo and in vitro study using 
PEG 900 however, an increased small bowel permeability was documented in senescent 
rats when compared to younger rats (Katz et al, 1987). The difference between the 
smallest polymer of PEG 900 (mw=800) and the largest polymer of the PEG 400 used 
in the present study (mw =642) is not great. The possibility therefore exists that either 
the age spectrum in the present study was not wide enough, or that polyethylene glycol 
400 may still, however , be too small a probe to detect an altered permeability within 
the age spectrum studied . 
PERMEABILITY STUDIES IN NORMAL SUBJECTS 
The PEG 400 excretory value for the control group (23 .85 %) is in agreement with 
those of other investigators. Chadwick (1977a) and Blatzinger et al (1981) using gas 
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chromatography found an excretion of 22-25 % of the ingested dose (10g) in controls. 
Jenkins et al (1986) found that the total 6-hour urinary PEG 400 excretion ranged from 
12.1 % to 35.9%. Robinson et al (1981) found a mean 6-hour urinary PEG 400 
excretion of 21.2 % following the oral ingestion of 10g of PEG 400. Magnusson found 
an average excretory value of 20% in a group of 24 healthy controls (Magnusson et al, 
1983). Maxton et al (1986) found an average 5-hour urinary excretion of PEG 400 of 
16% following the ingestion of 5 grams in 10 volunteers. In contrast, a mean excretion 
of 4% was found for the control group studied by Hollander (1986). This is at variance 
with the present study and other data in the literature. The methodology in this study 
involved lyophilisation of samples, and one can only speculate as study involved 
lyophilisation of samples , and one can only speculate as to whether the discrepancy 
could be explained 
if several or , possibly , all the urine samples from the controls were freeze dried in a 
single batch, and that loss of sample occurred in this step. 
Table 12. Urinary PEG 400 recovery in normal subjects 
Study Year Dose n % of ingested dose 
Chadwick et al 1977 10g 5 22 
Blatzinger et al 1981 10g 17 25 
Robinson et a1 1981 !Og 7 21 
Magnusson et al 1983 IOg 2 19 
Hollander et al 1986 5.6g 17 4 
* Time for urinary PEG recovery was 5 hours. All other studies time for urinary PEG 
recovery was 6 hours . 
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PERMEABILITY STUDIES: CROHN'S PATIENTS VERSUS CONTROLS 
No difference in PEG 400 excretion could be found between the patients with Crohn' s 
disease and the controls. These findings are in contrast with the findings of other 
investigators also using PEG 400 (Table 13). Jenkins et al (1986) and Magnusson et al 
(1983) found that patients with Crohn 's Di seas. While the exact number is not given, 
most of the patients in Magnusson' s study had previously undergone intestinal 
resections and a decreased uptake and excretion of PEG 400 would thus have been 
anticipated. Details of possible resections are not given for the fifteen patients 
comprising the Crohn's group studied by Jenkins' et al. Severity of disease may, 
however have been a factor , for all these patients had moderate to severe Crohn' s 
disease activity. In contrast to these studies , the patients witt to these studies, the 
patients with Crohn' s disease in the study of Hollander et al (1986) , were found to 
excrete up to twice the amount of PEG 400 when compared with the controls. While 
the values for the Crohn 's patients are comparable to those in the literature, the values 
for the control group as previously noted , were extremely low and not consistent with 
the literature. This may explain the apparent increased permeability in the patients, 
relative to the controls. Moreover , this finding is surprising in view of the fact that 7 
of the 11 Crohn' s patients in this study had previously undergone bowel resection and 
could have been expected to have a decreased rather than an increased excretion. 
Table 13. Urinary PEG 400 recovery in Crohn's patients and controls 
Investigators Crohn' s patients Controls 
n %recovered n %recovered 
Magnusson et al , 1983 24 14 24 20 
Hollander et al , 1986 11 9 17 4 
Jenkins et al , 1986 15 15 40 19 
Several investigators have found decreased small bowel permeability to PEG 1000 in 
Crohn's patients as opposed to controls (Heuman et al , 1982) (Olaison et al, 1987; 
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Olaisson et al , 1989). All the patients in the first study and a substantial percentage of 
the patients in the last study had , however, undergone previous bowel resections. As 
the effect of resection was found to be unrelated to permeability in the second study, an 
alternative explanation is that the decreased excretion is also reflective of absorptive 
defects in apparently uninvolved areas of bowel. 
Table 14. Summary of studies of intestinal permeability with Cr-EDTA in 
patients with Crohn's disease. 
Investigator Crohn's Controls Crohn's vs Controls 
n n 
Bjarnason et al , 1983 32 28 INCREASED 
Jenkins et al , 1985 54 48 INCREASED 
Peled et al , 1985 6 27 INCREASED 
Jenkins et al , 1987 100 80 INCREASED 
Ainsworth et al , 1989 15 28 INCREASED 
Studies in patients with Crohn 's disease and controls , companng unnary recovery, 
following ingestion of 51 cr-EDTA , have yielded more consistent results (Table 14). 
Patients with Crohn' s disease have been consistently found to excrete significantly more 
51cr-EDTA than healthy controls. Differences in probe characteristics and size may 
account for the variance of the data between 51 cr-EDTA and with that using PEG 400 
and PEG 1000. While the route of uptake of both PEG and 5 1cr-EDTA is thought to 
be via the tight intercellular junctions , their physiochemical characteristics differ 
markedly. 
The finding of an increased permeability in patients with Crohn's disease has also been 
demonstrated using the probe DTPA . In a study by Casellas et al (1986) , urinary 
recovery of DTPA was greater in 16 patients with Crohn's disease than in 10 healthy 
controls. This is in agreement with the findings of O'Morain et al (1984), where 
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patients with Crohn' s disease of the small bowel (n = 18) had a significantly higher 
urinary excretion than controls (n = 15). 
Tests using carbohydrates as probes have consistently shown an altered permeability as 
measured by the excretory ratios of sugars (Table 15). Analysis of the individual 
sugars of the ratio, however , show that, while in general , absorption of mannitol is 
decreased and that of lactulose increased in patients with Crohn' s disease as compared 
with controls, this is not always the case. Pearson et al (1982) found a large increase 
in permeability in 8 patients with Crohn 's disease when compared with 31 controls. 
Analysis of individual sugars reveals that while permeability to lactulose was increased 
in the patients relative to the control group, that of mannitol was unchanged. 
Furthermore, the test solution administered was hypertonic. In the study of Murphy et 
al (1989) and Katz et al (1989), while the urinary excretion of lactulose was increased, 
that of mannitol and rhamnose was unchanged in the patients with Crohn 's disease 
relative to controls. 
Table 15. Summary of studies of intestinal permeability using carbohydrate 
probes. 
Author Year 
Pearson et al 1982 
Ukabam et al 1983 
Sanderson 1987 
et al 
Andre et al 1988 
Murphy et al 1989 






















PERMEABILITY STUDIES IN RELATIVES 
No evidence of an altered small bowel permeability to PEG 400 could be found in 
patient relatives in the present study. This is in contrast with the only other study in 
the literature examining patient relatives using PEG 400 (Hollander et al, 1986) and 
consequently at variance with the concept of family members having occult 
inflammation or predisposing permeability disorder. Two other studies using different 
probe-markers , have examined small bowel permeability in relatives of patients with 
Crohn's disease (Table 16) . 
Table 16. Permeability in relatives compared with controls 
Investigator Year Probe Relatives vs Controls 
Ruttenberg et al 1989 PEG 400 NO DIFFERENCE 
Hollander et al 1986 PEG 400 INCREASED 
Ainsworth et al 1989 51 cr-EDTA NO DIFFERENCE 
Katz et al 1989 lactulose/ 
rhamnose/ mannitol NO DIFFERENCE 
All the probe-markers used , although of differing chemical characteristics, are of a 
similar size. As previously noted , PEG 400, 51 cr-EDTA and lactulose are thought to 
permeate via the paracellular route, while rhamnose and mannitol permeate via the 
transcellular route. In spite of this , no evidence of an altered permeability has been 
found in patient relatives. In the study using carbohydrate probes in relatives of 
patients with Crohn' s disease (Katz et al, 1989), neither lactulose, rhammnose nor 
mannitol could detect evidence of an altered permeability in family members. The 
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above data would therefore suggest that a primary defect is not, rn fact , present in 
patients with inflammatory bowel disease. 
SELECTIVE PERMEABILITY 
The composition of the PEG 400 in urine from all subjects was similar to that of the 
ingested dose. There was no evidence of preferential uptake and excretion of any 
individual PEG 400 polymers in the patients with Crohn' s disease, their relatives or the 
control group (Fig 8). This is in agreement with the findings of Jenkins et al (1986) 
and Blatzinger et al (1981) where no evidence of selective permeability to PEG 400 
was found in either the Crohn' s patients or the controls. In addition , no evidence of 
selective permeability could be found in patients' relatives in a recent study by 
Hollander et al (1986). This absence of selective permeability is in contrast with the 
findings of Maxton (1986) and Magnusson ( 1983) where considerably more of the 
smaller molecular weight species of PEG 400 were found in the urine of patients and 
controls. 
Table 17. Summary of studies using different sized PEG probes 
Investigator 
Blatzinger et al 
Magnusson et al 
Hollander et al 
Jenkins et al 
Maxton et al 
Olaisson et al 
Olaisson et al 
Tagesson et al 
Olaisson et al 














































While not comparable to oral absorption studies , Olaison et al (1988 , 1989) , could find 
no evidence of preferential uptake of the slightly larger PEG 600 (mw, 590-942) in a 
recent in vivo study , examining regional absorption in ligated loops of small bowel 
(Table 17). The contradictory evidence in the literature would suggest that selective 
permeability may not, however, be consistently apparent using lower molecular weight 
species of PEG. Indeed, the data for a selective permeability is more consistent with 
the higher molecular weight PEG 1000. Tagesson et al (1983) and Olaisson et al (1987 
and 1989) found that urinary recovery of orally ingested PEG 1000 (mw, 634-1294) 
was inversely proportional to the individual molecular weights in both patients with 
Crohn's disease and controls. An interesting finding by Olaisson et al in 1989, was the 
loss of selective permeability to PEG 1000 following direct colonic instillation of the 
marker in patients with Crohn' s disease. This would suggest that any filtering and 
preferential uptake occurs at the level of the small intestine. 
Following intravenous administration of PEG 400 in pigs , urinary recovery of PEG 
400 is directly proportional to molecular size for PEG 400, but not for PEG 1000 
(Tagesson & Sjodahl 1984). Indeed , capillary filtration of the smaller molecular 
weight PEGs may play an important role in sequestration of the latter into the 
extravascular space (Tagesson & Sjodahl 1984). Evidence of preferential permeability 
following orally administered PEG 400 must therefore take into account non-intestinal 
factors. 
EFFECT OF DISEASE SITE ON URINARY PEG RECOVERY 
Polyethylene glycol is thought to be absorbed primarily in the proximal small bowel 
and absorption decreases distally (Chadwick et al, 1977). The finding by Magnusson et 
al (1983) of a decreased excretion of PEG 400 in a patient after a jejuna! resection 
would seem to support this. 
In accordance with current thinking permeability to PEG 400 could be either increased 
or decreased in patients with ilea! disease . Some investigators have speculated about a 
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tightening of the cellular tight junctions with any inflammation. Bowel permeability to 
PEG 400 would, under these circumstances, be decreased. If, however, one subscribes 
to the theory of a widening and disruption of the paracellular junctions with 
inflammation and ulceration, then an increased permeability to PEG 400 would have 
been expected. While an altered permeability might therefore have been expected in 
patients with ilea] disease no difference in PEG 400 excretion between the patients with 
ileal disease and controls was found (Table 9). These findings are similar to those of 
Casellas et al (1986) using the similar sized probe, DTPA. The number of patients in 
the study of Resnick et al (1990) was too small to allow statistical analysis. 
The lack of differences in the present study may be a reflection of the probe size rather 
the probe structure. Some support for this may be found in the study by Olaison et al 
(1989), where, using PEG 1000 as the probe, patients with ileal Crohn's disease had 
decreased absorption when compared with controls (Olaison et al, 1989). 
Patients with colonic Crohn' s disease excreted a similar amount of PEG 400 as patients 
with ileal or ileocolonic disease or controls in the present study (Table 9). While there 
is no comparable data for PEG 400 , PEG 1000 was used as the probe in a recent study 
by Olaisson et al (1989) . This showed that , in patients with colonic disease, urinary 
recovery following an oral load of PEG 1000 was less than that in patients with ileal 
disease or controls (Olaisson et al, 1989) . This would be compatible with the theory of 
increased permeability due to inflammation and swelling of the tight junctions in the 
site of predominant PEG absorption. In attempting to reconcile the differences, the 
authors, however, suggested that the impaired colonic absorption relative to the 
controls may denote a more severe variant of Crohn 's disease. Similar results (of 
impaired colonic permeability relative to ilea! absorption) have also been found using 
the probe 51 cr-EDTA (Ainsworth et al, 1989) . Direct colonic instillation of the PEG 
1000 has been found to result in the reverse situation; i.e. urinary recovery of PEG 
1000 is greater from the patients with colonic Crohn' s disease than from the patients 
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with ileal disease (Olaison et al, 1989). The methodology used in the intracolonic 
administration involved instillation and deposition of the probe just below the splenic 
flexure in the colon thus excluding ileal permeability. It may be speculated that while 
these results may have been anticipated, it may alternatively, also reflect more severe 
colonic disease. 
There is conflicting evidence concerning the permeability to 
51 Cr-EDT A and sugars in 
patients with colonic disease. Both an increased (Bjarnason et al, 1983) and a similar 
(Ainsworth et al, 1989) excretion viz a viz controls has been reported with 
51cr-
EDTA. Methodological differences may account for these disparate results using the 
same probe. An alternative explanation (Bjarnason et al, 1983) was that it may also 
represent the heterogenicity found in Crohn' s colitis which is indistinguishable from 
ulcerative colitis in 10 to 15% of cases (Price 1978). 
Patients with colonic Crohn 's disease have been found to have either a decreased or an 
unaltered absorption of mannitol relative to controls (Ukabam et al, 1983; Andre et al, 
1988; Katz et al, 1989). Interestingly, although the number of subjects in the former 
study is small, no difference in intestinal permeability was found between the 7 colonic 
Crohn's and 16 controls as measured by lactulose absorption. Katz et al (1989) could 
also find no difference in lactulose absorption and excretion between patients with 
colonic disease and controls. This is in agreement with the findings of the present 
study. Lactulose and PEG 400 are of a similar size and are thought to permeate via 
paracellular tight junctions. The large number of conflicting results using the same 
probes would suggest that no probe is at present site specific. 
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EFFECT OF PREVIOUS BOWEL RESECTION ON URINARY PEG 
RECOVERY. 
A significantly lower PEG 400 excretion was evident in patients who had undergone 
previous resections, when compared with non-resected patients. As surface area may 
be related to absorption and permeability, these findings are compatible with an overall 
decreased uptake and excretion of PEG 400. No difference, however , in urinary PEG 
400 excretion was evident between patients with Crohn' s disease who had undergone a 
previous resection and the healthy controls. The possibility does , therefore, exist that 
this significance is due to statistical random chance. The findings of a lack of influence 
of intestinal resection (within the patient group) in at least two other studies, using 
carbohydrate probes , would seem to support this concept of statistical random chance 
(Andre et al, 1988; Katz et al , 1989). 
While a tendency towards a decreased absorption and excretion of PEG 400 was found 
by Hollander (1986) in his 7 patients who had undergone intestinal resections, no 
statistically significant differences could be found between them and the non-resected 
patients or the controls. The resected group in the present study included patients with 
varying lengths of bowel resection (Table 9). 
While the extent of surgery varied considerably between patients , there were too few 
patients in this group to correlate PEG 400 excretion and length of bowel resection. 
Only one study has thus far correlated length of intestinal resection and PEG excretion 
(Heumann et al, 1982) . Here, a negative correlation was found between length of 
resection and 6 hour urinary recovery of PEG 1000. A tendency towards a negative 
correlation was also found by Olaison et al (1987) . 
Surprisingly , an increased small bowel permeability to PEG 400 immediately (6 weeks) 
following intestinal resection has also been documented (Magnusson et al, 1983). 
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This, the only study companng urinary PEG recovery pre and post resection, was 
based on the findings in only two patients. 
Some support for these interesting findings can be found in animal studies. Changes 
are known to occur in the remnant small bowel of the rat following intestinal resection. 
Mucosal hyperplasia occurs and is usually considered maximal at about 4 weeks post 
resection (Williamson et al, 1978). An increased mucosal cell turnover in the remnant 
small bowel may manifest as a consequent functional immaturity with an associated 
increased permeability . In a recent study in rats, using 14c-erythritol, the effect of 
extent of small bowel resection on erythritol clearance was studied in the small and 
large bowel, 4 weeks post resection (Vacquez et al, 1988). It is noteworthy that a 
significantly increased clearance of erythritol per unit small bowel mass was found only 
when 80% of the small bowel had been resected . Erythritol and PEG 400 are thought 
to have similar routes of permeation via the paracellular junctions. While the increase 
in permeability in the above animal study may be compatible with the increase found 
by Magnusson (1983) , it is highly unlikely that his patients had had an 80% small 
bowel resection. 
The increased permeability documented in the above animal studies after surgical small 
bowel resections may be related to the probe size. Olaison et al (1989) could find no 
differences in 6 hour urinary recovery of PEG 1000 between patients with and without 
ileostomy and between patients with and without previous colectomy. Uban et al 
(1983) could also find no evidence of an altered permeability to the even larger PEG 
4000 in the small bowel of resected and sham operated rats (Urban et al, 1983). 
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EFFECT OF DISEASE ACTIVITY ON URINARY PEG RECOVERY. 
Disease activity as assessed by clinical and laboratory indices did not seem to influence 
permeability to PEG 400. Both the NCCD (Best et al, 1976) and van Rees (Van Rees 
et al, 1980) activity indices were used as more objective assessments of disease activity. 
With either index, a score of less than 150 is indicative of disease remission. Most of 
the patients with Crohn' s disease were clinically well according to the NCCD index 
(Table 10) . If intestinal permeability to PEG 400 in any way reflects inflammatory 
change and mucosal damage, either an increased, or a decreased permeability to PEG 
400 should have been evident in the patients who were ill. This was not so in this 
study where no difference in urinary PEG 400 excretion was found between the patients 
who were well and the patients with more active disease. This is in agreement with the 
data of Olaison using the larger sized PEG 1000 where no differences in urinary PEG 
1000 recovery could be found between non-resected inactive patients (n = 11), and 
previously resected patients with active (n=14) and inactive (n=19) disease (Olaison et 
al, 1987) . 
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Results of permeability studies and disease activity are contradictory (Table 18). 
Table 18. Influence of disease activity on intestinal permeability 
Investigator Year 
Present study 1989 
Olaison et al 1987 
Jenkins et al 1987 
Ainsworth et al 1989 
Bjarnason et al 1983 
Casellas et al 1986 
Resnick et al 1990 
Ukabam et al 1983 
Gomes et al 1983 
Sanderson et al 1987 






























Several groups have studied the relationship between disease activity and permeability 
to 5 lcr-EDTA. While Jenkins et al (1987) found a significant increase in patients with 
active disease, Ainsworth et al (1989) and Bjarnason et al (1983) found no relationship 
between disease activity and permeability to Slcr-EDTA. The latter findings are in 
agreement with those of the present study. 
Casellas et al ( 1986) and Resnick et al (1990) both found a direct relationship between 
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disease activity and permeability to DTPA. 
Contradictory findings have also been made in studies using carbohydrates as probes. 
While the findings of the present study are in agreement with those of Ukabam et al 
(1983) who could find no correlation between disease activity and permeability to these 
sugars in 20 patients with Crohn's disease, they are in contrast with those of Gomes et 
al (1983), Sanderson et al (1987) and Murphy et al (1989). The use of different 
disease activity indices may account for these discrepancies. Permeability to mannitol 
and lactulose has more recently been found to correlate with CDAI as predictors of 
disease relapse (Valpiani et al , 1990). 
EFFECT OF TREATMENT ON URINARY PEG 400 RECOVERY. 
Overall , treatment did not influence urinary PEG 400 excretion. Indeed most of the 
patients with Crohn' s disease were not on medication of any kind. In view of their 
mode of therapeutic action, a decreased absorption of PEG 400 might have been 
anticipated , in patients on oral steroids due to the reduction in inflammation. No 
conclusions , however, could be drawn from individual treatment regimes in the present 
study because of the relatively sma11 numbers of patients involved. 
These findings are also in agreement with the findings of Jenkins et al (1987), where 
urinary recovery of 51cr-EDTA was independent of medication. 
The use of an elemental diet in the management of patients with Crohn' s disease has 
been found to result in an improvement in the altered permeability as reflected by the 
excretory ratio of mannitol and rhamnose (Sanderson et al, 1987) . This data would 
support the concept of the inflammatory changes being a secondary rather than a 
primary phenomenon. 
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CHAPTER SEVEN: COMPARISON BETWEEN PEG 400, SlCR-EDTA, DTPA 
AND CARBOHYDRATE PROBES. 
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The molecular size spectrum that comprises PEG 400 coincides with rhamnose and 
mannitol at one end, and lactulose and 5 l Cr-EDT A at the other end. In only two 
studies has PEG 400 been compared with these similar sized probes. These studies 
have involved the simultaneous ingestion of lactulose, mannitol, 
51 Cr-EDT A and PEG 
400. In the study by Maxton et al (1986), 10 volunteers ingested lactulose (mw=342), 
rhamnose (mw= 164), PEG 400 (mw=400) and 51cr-EDTA (mw=340), 
simultaneously in the form of an isotonic solution. Paper, thin-layer and gas 
chromatography were used in urinary analysis of probes collected over a 24 hour 
period, following oral and intravenous administration . The effect of a hyperosmolar 
solution on urinary recovery was also examined . 
Following intravenous administration, the percentage urinary recovery of all the 
markers with the exception of PEG 400, was almost complete. While the overall 
urinary recovery of PEG 400 was much lower (40%), a linear relationship between the 
individual polymer size of PEG 400 and percentage urinary recovery was observed. 
This supports the concept of urinary underestimation of PEG 400 following oral 
administration and furthermore, as renal clearance of PEG 400 is similar to that of 
creatinine (Robinson et al, 1981), also suggests sequestration into the tissues (Maxton 
et al, 1986). 
Following oral ingestion of all the markers, intestinal permeation was greatest in the 
first 6 hours of urinary collection. Quantitatively, however, permeation of individual 
polymers of PEG 400 was markedly greater than the other markers. Maxton found that 
at the lower end of the spectrum, permeation by the PEG 400 polymer with a 
molecular weight of 194 was 3 times greater than the similar sized rhamnose. 
Permeation of the PEG 400 polymer with a molecular weight of 326 was over 100 
times greater than the similar sized lactulose and 5 lcr-EDTA (Maxton et al, 1986). 
The response to the hyperosmolar stress by PEG 400 also differed to that shown by the 
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other probe-markers. While increased permeation was found to all probe-markers, no 
correlation could be found between PEG 400 and the others. 
All the above data support the concept of two pathways of permeation in the small 
intestine. Particles with a radius of less than 0.4nm pass mainly through numerous 
small pores. Molecules with a larger radius like lactulose (radius greater than 0.5nm) 
would seem to pass through a few larger sized pores. While the exact route of PEG 
400 uptake is unclear at present, it would seem to involve partition through the lipid 
cell membranes as well as via pores (Maxton et al, 1986). 
No correlation has thus been found between the permeation of PEG 400 and lactulose, 
51cr-EDTA, L-rhamnose or D-mannitol (Maxton et al, 1986). In a more recent study 
in smokers and non-smokers by Prytz et al (1989), no correlation between urinary 
recoveries of 51 cr-EDTA and the urine recoveries of PEG 400 could be found. 
Intestinal pathways for PEG 400 thus do not relate specifically to other similar sized 
molecules. 
While the carbohydrates have been used as markers of an altered intestinal 
permeability , their value is best seen when urinary recovery is expressed as a ratio. 
Thus, patients with Crohn' s disease have an elevated ratio when compared with 
controls. From the literature, it would seem that results of individual sugar 
quantitation are not consistent between patients and controls. While a marker of 
disease presence and, maybe, disease activity, their role in association with disease site 
needs further evaluation in view of the discrepancies already found between 
investigators. Furthermore, a morphologically abnormal small bowel mucosa does not 
seem to be a prerequisite for an abnormality in permeability, as measured by sugar 
excretory ratios. Strobel et al (1984) found a group of patients with normal jejuna! 
histology associated with abnormal permeability to the carbohydrates mannitol, 
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cellobiose, sucrose and lactose. As noted previously, hypertonicity per se may alter 
intestinal permeability (Laker and Menzies, 1977)(Wheeler et al, 1978). The increase 
in small intestinal permeability to lactulose appears to be especially marked when the 
lactulose is given in a hypertonic solution (Budillon et al, 1982). Leaky and disrupted 
tight junctions as a result of the hypertonicity per se could explain this (Laker and 
Menzies, 1977). 
While a useful probe, the use of 5 l Cr-EDT A, as a screening test for patients with 
Crohn's disease, would seem to be limited by its large intra-individual variation in 
normal subjects and the fact that significant quantities are absorbed in the normal colon. 
In addition, it does not seem to be a useful marker for site or degree of inflammatory 
disease. 
[99mTc]DTPA would seem to have distinct advantages as a probe of intestinal 
permeability over either PEG or 51 cr- EDTA. Further studies are needed, however, 
to evaluate its potential role as a marker of site of disease and to evaluate the effect of 
previous bowel resection on urinary recovery. 
Small quantities of PEG 400 are absorbed under normal circumstances. The use of 
entirely non-absorbable larger PEGs would thus be preferable. Indeed, certain 
polyethlyene glycols are virtually non-absorbed (Shaffer 1947). Golytely, a colonic 
lavage preparation, consists largely of PEG 3350 and its absorption has been 
extensively studied. Only 0.06% of an oral dose could be recovered in the urine of 10 
volunteers over 2 days. Schedl et al (1966), using turbidimetric methods, were unable 
to demonstrate any urinary PEG 400 excretion, following steady state intestinal 
perfusion with the probe. It is not known, however, whether complete recovery of the 
intraluminal solution was possible in these early experiments. Shields et al (1968), also 
showed complete recovery of the larger molecular weight PEG 4000 in rectal effluent, 
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following perfusion of the human colon with this marker. 
Other workers have shown that the quantity of polyethylene glycol 4000 that can be 
recovered in the stools following oral ingestion , varies from 75 % (Beeken 1967) to 
97% (Hyden 1956). In this latter study, however, more PEG was found to be excreted 
in the urine than had been orally ingested in some of the subjects. Methodological 
differences could account for discrepancies between these and later studies. 
The use of polyethylene glycol 400 as a permeability probe has been questioned. In 
addition to its size, excretion of PEG 400 into the urine is not solely dependent on the 
gut mucosal permeability, but also its space of distribution in the body and permeability 
profile by the kidney (Blatzinger et al, 1981). Studies have shown, however, no 
relationship between urinary volume and renal clearance and PEG 400 excretion 
(Robinson et al, 1981). Nevertheless, data on sites and routes of sequestration of PEG 
400 is not available at present. 
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CHAPTER EIGHT: SUMMARY 
72 
The literature is replete with conflicting and confusing data regarding altered small 
bowel permeability in patients with Crohn' s Disease. An increased and a decreased 
permeability have been documented to PEG 400 and other similar sized probes . 
A new more sensitive and accurate HPLC technique for the analysis of PEG 400 was 
developed and compared with the previously described extraction method. There was 
good analytical recovery (94-102%) and reproducibility (CV=3.3%) . Direct injection 
of dilute urine samples onto the analytical column proved to be more economical in 
time and chemicals and also allowed a rapid rate of analysis. 
The direct injection method was subsequently used to examine intestinal permeability 
in a group of patients with Crohn' s disease, some of their first degree relatives and a 
group of healthy controls . A wide scatter in urinary recovery was evident in all the 
subjects studied. The wide scatter of results found in the present study was, however, 
not related to technical or methodological reasons. 
There was no evidence of an altered permeability to PEG 400 between patients with 
Crohn' s disease, their relatives or healthy controls. The 6 hour urinary recovery of 
orally ingested PEG 400 was found to be independent of the following variables: age, 
sex, site of disease, bowel resection, inflammatory disease activity and medication. 
The results found in the present study are in accord with those of the literature with 
respect to the lack of association between age, sex, disease activity and medication and 
intestinal permeability as measured by the urinary recovery of orally ingested PEG 400. 
There does not, however, seem to be agreement on the influence of the presence and 
site of disease, and the effect of previous bowel resection. 
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CHAPTER NINE: CONCLUSION 
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In spite of the examination of a larger group of subjects than has previously been 
studied, and the use of refined, more sensitive and accurate technology, no evidence of 
an altered bowel permeability to PEG 400 could be found between subjects with 
Crohn's disease and healthy controls or in relatives of patients with Crohn's disease. 
The wide scatter in results, the test-retest reliability coefficient of 0. 74, together with 
the lack of concurrence in the literature, would suggest that, either no altered intestinal 
permeability difference exists in patients with Crohn' s disease, or that PEG 400 is not 
the ideal probe with which to examine this. 
The pathways of uptake and physiochemical characteristics of smaller sized molecules 
differ. The findings and presence of an altered permeability to any one molecule 
cannot be extrapolated and do not necessarily correlate with an altered permeability to 
another similar sized molecule. The only conclusion that can be drawn is that an 
altered permeability exists with respect to that particular probe. 
The existence of an altered bowel permeability to such a molecule may not, rn any 
event, be of clinical relevance, as most antigenic molecules are up to 50 times larger. 
As most studies have confined themselves to the smaller sized probes without antigenic 
properties, this question remains largely unanswered . 
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